Interview with Tom Keith Roach, President, AstraZeneca South Korea
You have recently taken over the position as head of AstraZeneca in South Korea, after several years working in China. What view did you have of the Korean pharmaceutical sector…
Established in 1960, CHA Health Systems (CHS) opened its first women’s medical center in Seoul, South Korea. CHS has received worldwide recognition and accolades for its excellence in clinical research and accomplishments in the fields of obstetrics and gynecology. It owns and operates, among others: Hollywood Presbyterian Medical Center, one of the largest privately-owned hospital in Los Angeles and 8 general acute-care hospital facilities throughout Korea. CHS continued its international expansion and formed CHAUM, a premier anti-aging center and 5 fertility treatment and research centers in the U.S. and Korea. The Company’s activities also include various medical and biotech ventures, including a healthcare investment firm, CHA Bio & Diostech, one of the largest biotechs listed in KOSDAQ.
CHS also introduces a premier anti-aging center, CHAUM, offering various treatments including western medicine, alternative medicine, stem-cell therapies, exercise prescription, and food therapies, targeting issues related to optimum health and wellness. It also operates a global CHAUM clinical trial center, the world’s only one-stop clinical trial center for regenerative medicine. In this center, GMP facility, surgery room, recovery room, treatment room, and in-hospitalization facility are centrally located for convenience and quality care. Its customized clinical trial services and state-of-the art facilities for the development of regenerative medicine are a major supplier to many biotech companies worldwide, which offers opportunities for small and large companies to carry out proof of concept studies and early phase clinical trials at substantial savings in time and money.
With the ultimate vision of becoming a global leader in the next generation of healthcare services, CHS continues to stay at the forefront of medical services by building its global network of hospitals/clinics and research institutes for the advancement of bio-medicine and bio-ventures.
Contact Details
Dong-kun Lee, Corporate Planning
335 Pangyo-Ro, Bundang-Gu, Seongnam City, Kyunggi-Do, Republic of Korea
Tel. (+82)31-881-7370 Cell (+82)10-9261-6160 Fax. (+82)31-881-7379
E-mail. ddkk.lee@chamc.co.kr
You have recently taken over the position as head of AstraZeneca in South Korea, after several years working in China. What view did you have of the Korean pharmaceutical sector…
You are one of the foreign multinational directors with most time in the Korean pharmaceutical industry, since 2003. What is your assessment of the direction the market has taken in…
What is KHIDI’s role in supporting the development of the Korean health industry? KHIDI performs three major roles in supporting the Korean health industry, which includes pharmaceuticals, medical devices, cosmetics,…
Previous to your current position as President of Pfizer Korea since 2004, you had been in the country between 1989 and 1993 as sales and marketing director. How different are…
Please introduce Handok Pharmaceuticals to our readers, and in particular how it has evolved through partnerships with different multinational companies throughout its history. Handok has developed in a very unique…
Korea had a late start, but is now one of the global hot spots for clinical trials. How would you sum up and explain this quick evolution? Clinical trials in…
You have been in South Korea for several months, following some time as Merck’s President in Pakistan. In your opinion, what do you find as the most interesting aspects of…
What was the vision behind the creation of Neurotech back in 1998, originally as a Research Center, and then as an independent bio-tech company? It all began in 1998 when…
You have recently been appointed as General Manager of Servier in South Korea, after coming from several years working in Europe. What perception did you have of the far-way Korean…
Since KRPIA’s creation in 1999, what would you say have been its main achievements in the South Korean pharmaceutical landscape? KRPIA’s foremost achievement during its existence has been its contribution…
What was the vision behind the creation of the Korea Drug Research Association and its main role in the pharmaceutical sector? Until the middle of the 1980s when Korea Drug…
Could you briefly introduce VGX International to our readers, and in particular explain its relation to US-based company VGX Pharmaceutical (VGXP)? The backbone of VGXP is the University of Pennsylvania…
See our Cookie Privacy Policy Here
